Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Epicrispr Biotechnologies closed a $90 million Series C financing round, led by Octagon Capital and Janus Henderson Investors, to push EPI-321 into pivotal trials.
PRIVATEAug 10, 2026•about 3 hours ago
Amount Raised
$90 Million
Round Type
Series C
San FranciscoBiotechnologyHealth CareGeneticsTherapeuticsInvestors
Readout CapitalAngelini VenturesAbrdn Inc.Sanofi VenturesDuquesne Family OfficeCormorant Asset ManagementFidelity Management & Research CompanyJanus Henderson InvestorsOctagon Capital
Description
Epicrispr Biotechnologies has secured a $90 million Series C financing round, oversubscribed and supported by a notable array of investors including Fidelity and Sanofi Ventures. This funding will focus on advancing EPI-321, its lead candidate for treating facioscapulohumeral muscular dystrophy, through pivotal clinical development. The company aims to demonstrate that gene silencing can become a viable therapeutic option without altering DNA. This significant investment reflects growing confidence in epigenetics as a therapeutic modality.
Related People
Suggested for you
1 contactVerified contactsNo contacts on file at Epicrispr Biotechnologies yet.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech